INmune Bio, Inc. (NASDAQ:INMB) Short Interest Up 20.2% in January

INmune Bio, Inc. (NASDAQ:INMB) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 3,896,241 shares, a growth of 20.2% from the December 31st total of 3,241,827 shares. Based on an average daily trading volume, of 342,062 shares, the days-to-cover ratio is presently 11.4 days. Approximately 18.6% of the shares of the company are short sold. Approximately 18.6% of the shares of the company are short sold. Based on an average daily trading volume, of 342,062 shares, the days-to-cover ratio is presently 11.4 days.

INmune Bio Trading Down 1.9%

Shares of INMB stock opened at $1.52 on Thursday. The company has a market capitalization of $40.40 million, a P/E ratio of -0.72 and a beta of 0.72. The business’s 50 day moving average is $1.71 and its two-hundred day moving average is $1.93. INmune Bio has a 12-month low of $1.38 and a 12-month high of $11.64.

Wall Street Analysts Forecast Growth

INMB has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of INmune Bio in a report on Wednesday, October 8th. Wall Street Zen raised shares of INmune Bio from a “sell” rating to a “hold” rating in a research note on Sunday, December 14th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $15.50.

Institutional Investors Weigh In On INmune Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in INMB. Intech Investment Management LLC acquired a new position in INmune Bio during the second quarter worth $26,000. PFG Investments LLC purchased a new stake in shares of INmune Bio during the second quarter worth about $27,000. Cary Street Partners Financial LLC acquired a new position in shares of INmune Bio during the 3rd quarter worth about $29,000. Squarepoint Ops LLC acquired a new position in shares of INmune Bio during the 3rd quarter worth about $30,000. Finally, Independent Advisor Alliance purchased a new position in INmune Bio in the 3rd quarter valued at about $30,000. Hedge funds and other institutional investors own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.